Key Account Manager

Albert raises $55M to scale chemistry-native AI. Albert, developer of the first chemistry-native AI operating system for R&D, announced a $55 million Series B funding. The Series B funding is led by TCV with participation from new investors Delta-V Capital, Socium Ventures, HighSage Ventures, Coral Capital, and Legion VC. They are joined by existing investors Coatue, J.P. Morgan Growth Equity Partners, Index Ventures, and Applied Ventures. The new funding will be used to expand Albert's chemistry-native AI capabilities, shortening development cycles and reducing time to market for the everyday products used by billions of people. As companies race to adapt to shifting safety and regulatory requirements, supply chain disruptions, and customer expectations for faster timelines, leveraging AI for product development is becoming increasingly critical. Albert was built specifically for the complexity of chemistry and materials science, combining chemistry-native AI with the security, governance, and scale required by global enterprises, including zero data retention, fine grained access controls, and reasoning audit trails. General-purpose models consistently fail to support specialized workflows in highly sensitive industries like legal, finance, and science. In enterprise R&D, scientists need highly specific AI capable of distinguishing between formulations, materials, processes, and experimental conditions that can look nearly identical in language but behave very differently in practice. Albert created a benchmark for formulation chemistry called "FormBench," which sets a new global standard for evaluating AI in this context. Albert also announced the industry-defining success of its chemistry-native model "Valence" which new research shows is 45x more accurate than general-purpose AI at retrieving the correct answers to scientific queries. Valence achieves this improved performance because it was trained to discriminate chemical composition and function while reading text, the way an experienced chemist would. "Enterprise AI for chemistry has to be built from the ontology up; the language, data, workflows, and decisions for R&D are deeply specialized. Because our team comes from the chemical industry, we've built Albert around that reality, pairing a scientific ontology with chemistry-native AI in a way that is tailored for each customer. This funding supports our vision of enabling customers to build a world model of their unique science, one that is grounded in their real experimental data," said Nick Talken, CEO and co-founder of Albert. "R&D in chemistry still runs largely on spreadsheets and institutional memory," said Morgan Gerlak, Partner, TCV. "Albert turns decades of lab data into faster discovery, and it represents what we think the future of vertical AI should look like." Albert's chemistry-native AI brings together the scientific ontology, intelligence, integrations, and regulatory compliance required to support R&D across large organizations, with partners such as AkzoNobel, Avient, BASF, Chemours, Clorox, Henkel, Kenvue, and Nouryon. Scientists can interact with natural language, and Ask Albert orchestrates a sophisticated harness of the tools, agents, and models to accelerate invention: surfacing institutional knowledge so teams don't repeat work, suggesting formulation candidates and designing experiments to shorten development cycles, and running complex data analysis to accelerate decisions. "We are proud of what we've accomplished together with Albert and are even more excited about the next steps on our shared roadmap. As a result of the partnership, we have increased R&D's ability to be interconnected across a common data platform, enabling the acceleration of how we develop new products for our consumers," said David Lutness, Head of R&D Digital Capabilities at Kenvue, maker of consumer health products like Zyrtec, Neutrogena, and Listerine. "In a global organization like ours, the challenge is never a lack of data, it's connecting it. Ask Albert lets our teams query everything in one place, from raw materials to notebook entries, instead of hunting across systems. We're still early, but it's clear this is going to reshape how we manage knowledge across R&D," said Milena Rosso-Vasic, Program Manager at one of the world's largest paint manufacturers, AkzoNobel. Over the past year, Albert has continued to expand across enterprise chemistry and materials R&D: Project creation has grown 26x year over year as organizations deploy Albert OS as shared infrastructure across their R&D functions. The user base has also multiplied, with 6x more scientists on Albert OS year over year, spanning 44 countries. This growth in adoption also includes increasingly diverse chemistry, with 4x more workflow creation year over year as more teams bring different R&D processes onto the platform. Albert's product capabilities have expanded just as rapidly: in six months, Ask Albert evolved from an AI search assistant to a full R&D partner that reasons across all of Albert OS. Company. 492 9th St, Suite 260 CA 94607 Oakland US

$CC investors: A Securities Fraud Class Action is pending on behalf of Chemours investors that lost money after 18% Stock Drop - Contact BFA Law by December 7 Deadline. Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products. NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company's senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit. Key Details of the Chemours ($CC) Class Action: * Lead Plaintiff Deadline: December 7, 2026 * Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon products * Stock Drop: August 5, 2026 - 18.63% Stock Drop * Court: U.S. District Court for the District of Delaware * Action: Contact BFA Law to discuss your rights Investors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299. Why is Chemours Being Sued for Securities Fraud? Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer. According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the AIM Act. What's more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M - $900M, driven by "higher... demand" in its Opteon segment. As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an "oversupplied channel heading into 2026." Why did Chemours's Stock Drop? On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M - $825M from $800M - $900M). Chemours also revealed that customers had "built additional inventory" of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an "oversupplied channel heading into 2026." On this news, Chemours's stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026. What Can You Do? If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes.

The Chemours Company securities fraud Class Action result of overstatement of refrigerant aftermarket demand and 18% stock decline - investors may contact Lewis Kahn, esq., at Kahn Swick & Foti, LLC. NEW YORK & NEW ORLEANS-(BUSINESS WIRE)-Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired the Company's securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware. What You May Do If you purchased securities of Chemours as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3615 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-cc/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 7, 2026. About the Lawsuit Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775-$825 million, down from $800-$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that... probably should have been allocated to more of this year." On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026. The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299. KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services >>>For More Information about the case, Click HERE Contacts. Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-833-538-3615 1100 Poydras St., Suite 960 New Orleans, LA 70163